The anti-hyperglycemic effect of Solenostemma argel compared with Glibenclamide

The current study aimed to compare the anti-hyperglycemic effect of Solenostemma Argel, which widely used for the treatment of diabetes mellitus in Sudan, with the antidiabetic drug (Glibenclamide). Twenty four albino rats were used in this experiment. Rats were assigned to 4 groups (N=6). All groups have fasted for 18 hrs. Group (1) was administered with glibenclamide (10 mg/kg b.w.) and served as control, groups (2, 3, and) were orally administered with aqueous extract of Solenostemma Argel leaves and bark (200, 400, and 800 mg/kg b.w.), respectively, after loading with 5% glucose (2 mg/kg b.w). Blood samples were obtained to assess blood glucose, lipid profile and α-amylase concentrations. Subchronic toxicity of Solenostemma Argel has been evaluated which clearly demonstrated the non-toxic nature and safety profile. Obtained results indicated that Solenostemma Argel aqueous extract significantly decreased blood glucose level in treated group received 800 mg/kg b.w. compared with glibenclamide treated group. At the dose of 200 mg/kg b.w. of Solenostemma Argel aqueous extract, the activity of α-amylase decreased in comparison with that treated with glibenclamide and registered low concentrations of cholesterol and HDL as well. In conclusion, both blood glucose level and α-amylase activity can be ameliorated in diabetic rats by administration of Solenostemma Argel aqueous extract. However, in prospective study more investigation has should be carried out to explain the mechanism of Solenostemma Argel in hypoglycemic animals